Nwam LLC Has $6.23 Million Holdings in Insmed, Inc. $INSM

Nwam LLC decreased its holdings in Insmed, Inc. (NASDAQ:INSM) by 21.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 38,982 shares of the biopharmaceutical company’s stock after selling 10,556 shares during the period. Nwam LLC’s holdings in Insmed were worth $6,226,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares in the last quarter. CoreCap Advisors LLC acquired a new position in shares of Insmed in the 4th quarter valued at $27,000. Stone House Investment Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. raised its stake in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in shares of Insmed in the 4th quarter valued at $30,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays upped their target price on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Wells Fargo & Company lowered their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Roth Mkm reaffirmed a “buy” rating and issued a $212.00 target price on shares of Insmed in a report on Friday, April 17th. Finally, Stifel Nicolaus upped their target price on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $211.86.

Insmed Stock Down 3.6%

Shares of NASDAQ:INSM opened at $101.17 on Friday. Insmed, Inc. has a 12 month low of $64.85 and a 12 month high of $212.75. The company’s 50-day moving average price is $145.87 and its two-hundred day moving average price is $165.46. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The firm has a market cap of $21.84 billion, a P/E ratio of -17.60 and a beta of 0.89.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 121.03%. The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the prior year, the firm earned ($1.42) EPS. The company’s revenue was up 229.7% on a year-over-year basis. As a group, research analysts forecast that Insmed, Inc. will post -2.41 EPS for the current fiscal year.

Insider Activity

In other news, insider Michael Alexander Smith sold 19,638 shares of the firm’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the transaction, the insider owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $17,584,130.30. This trade represents a 45.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 174,589 shares of company stock valued at $27,441,807. 2.10% of the stock is currently owned by insiders.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.